The phase 3 trial compares trastuzumab deruxtecan (Enhertu; AstraZeneca, Daiichi Sankyo) in combination with pertuzumab (Perjeta, Genentech) vs. current first-line standard of care in patients ...

Enhertu (6.4 mg/kg) is approved in more than 70 countries worldwide for the treatment of adult patients with locally advanced or metastatic HER2 positive (IHC 3+ or IHC 2+/ISH+) gastric or ...

In this primary analysis of DESTINY-PanTumor02, Enhertu demonstrated a median PFS of 6.9 months and a median OS of 13.4 months in the overall trial population. In the endometrial cancer arm, Enhertu ...

Daiichi Sankyo therapeutic area oncology development head Mark Rutstein said: “Following the positive results in the endometrial cancer cohort of DESTINY-PanTumor02, which contributed to a ...

The first patient has been dosed in the DESTINY-Endometrial01 phase 3 trial evaluating ENHERTU ® (trastuzumab deruxtecan) in combination with rilvegostomig or pembrolizumab versus platinum-based ...

DESTINY-Endometrial01 is a global, multicenter, randomized, open-label phase 3 trial evaluating the efficacy and safety of ENHERTU (5.4 mg/kg) in combination with rilvegostomig or pembrolizumab versus ...

Those are the 30 best creative Punch Hole wallpapers for Android. To set them as a wallpaper, click on the download button below the wallpaper, and it will redirect you to Google Drive.

Two American icons have come together for a collaboration that invites adventurers to live amongst design legacy like never before. Today Airstream, the Ohio-based travel trailer company known for its ...

Angus Liu breaks down phase 3 data on Enhertu from AstraZeneca and Daiichi Sankyo, while Gabrielle Masson overviews Bicara Therapeutics' investigational asset for head and neck squamous cell ...

On a recent sun-kissed afternoon in midtown Los Angeles, around 100 art-lovers gathered for a guided walkthrough of the new Diane Arbus retrospective at blue chip dealer David Zwirner’s flagship ...

Median duration of follow-up was nearly 2.5 years (29.2 months). As of the data cut-off, 302 (39.6%) patients remained on treatment, 174 in the ENHERTUplus pertuzumab arm and 128 in the THP arm.. The ...